The IPO of Senores Pharmaceuticals saw a strong investor response, with total subscriptions exceeding 93.41 times by the close.
Motilal Oswal initiates coverage on Adani Enterprises with Buy, sees 25% upside. Here’s why
Motilal Oswal has initiated coverage on Adani Enterprises with a Buy rating and a target price of Rs 3,880, implying 25% upside from the prevailing